Annual CFO
-$206.30 M
-$172.20 M-504.99%
31 December 2023
Summary:
Emergent BioSolutions annual cash flow from operations is currently -$206.30 million, with the most recent change of -$172.20 million (-504.99%) on 31 December 2023. During the last 3 years, it has fallen by -$743.20 million (-138.42%). EBS annual CFO is now -138.42% below its all-time high of $536.90 million, reached on 31 December 2020.EBS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$153.70 M
+$106.20 M+223.58%
30 September 2024
Summary:
Emergent BioSolutions quarterly cash flow from operations is currently $153.70 million, with the most recent change of +$106.20 million (+223.58%) on 30 September 2024. Over the past year, it has increased by +$93.70 million (+156.17%). EBS quarterly CFO is now -53.15% below its all-time high of $328.10 million, reached on 31 December 2021.EBS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$170.70 M
+$93.70 M+121.69%
30 September 2024
Summary:
Emergent BioSolutions TTM cash flow from operations is currently $170.70 million, with the most recent change of +$93.70 million (+121.69%) on 30 September 2024. Over the past year, it has increased by +$316.30 million (+217.24%). EBS TTM CFO is now -68.21% below its all-time high of $536.90 million, reached on 31 December 2020.EBS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EBS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -505.0% | +156.2% | +217.2% |
| 3 y3 years | -138.4% | +820.4% | -28.3% |
| 5 y5 years | -593.5% | +5058.1% | +270.9% |
EBS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -138.4% | at low | -53.1% | +183.5% | -46.7% | +161.1% |
| 5 y | 5 years | -138.4% | at low | -53.1% | +183.5% | -68.2% | +161.1% |
| alltime | all time | -138.4% | at low | -53.1% | +183.5% | -68.2% | +161.1% |
Emergent BioSolutions Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $153.70 M(+223.6%) | $170.70 M(+121.7%) |
| June 2024 | - | $47.50 M(-175.9%) | $77.00 M(-190.7%) |
| Mar 2024 | - | -$62.60 M(-295.0%) | -$84.90 M(-58.8%) |
| Dec 2023 | -$206.30 M(+505.0%) | $32.10 M(-46.5%) | -$206.30 M(+41.7%) |
| Sept 2023 | - | $60.00 M(-152.4%) | -$145.60 M(-47.9%) |
| June 2023 | - | -$114.40 M(-37.8%) | -$279.60 M(+54.6%) |
| Mar 2023 | - | -$184.00 M(-298.3%) | -$180.80 M(+430.2%) |
| Dec 2022 | -$34.10 M(-110.6%) | $92.80 M(-225.4%) | -$34.10 M(-116.9%) |
| Sept 2022 | - | -$74.00 M(+374.4%) | $201.20 M(-31.1%) |
| June 2022 | - | -$15.60 M(-58.2%) | $291.90 M(+5.1%) |
| Mar 2022 | - | -$37.30 M(-111.4%) | $277.80 M(-13.2%) |
| Dec 2021 | $320.20 M(-40.4%) | $328.10 M(+1864.7%) | $320.20 M(+34.5%) |
| Sept 2021 | - | $16.70 M(-156.2%) | $238.10 M(-27.1%) |
| June 2021 | - | -$29.70 M(-682.4%) | $326.60 M(-32.5%) |
| Mar 2021 | - | $5.10 M(-97.9%) | $484.20 M(-9.8%) |
| Dec 2020 | $536.90 M(+185.6%) | $246.00 M(+133.8%) | $536.90 M(+30.0%) |
| Sept 2020 | - | $105.20 M(-17.7%) | $413.00 M(+35.5%) |
| June 2020 | - | $127.90 M(+121.3%) | $304.70 M(+116.1%) |
| Mar 2020 | - | $57.80 M(-52.7%) | $141.00 M(-25.0%) |
| Dec 2019 | $188.00 M(+349.8%) | $122.10 M(-4038.7%) | $188.00 M(-288.2%) |
| Sept 2019 | - | -$3.10 M(-91.3%) | -$99.90 M(-229.4%) |
| June 2019 | - | -$35.80 M(-134.2%) | $77.20 M(-47.7%) |
| Mar 2019 | - | $104.80 M(-163.2%) | $147.60 M(+253.1%) |
| Dec 2018 | $41.80 M(-79.9%) | -$165.80 M(-195.3%) | $41.80 M(-85.3%) |
| Sept 2018 | - | $174.00 M(+402.9%) | $285.09 M(+95.2%) |
| June 2018 | - | $34.60 M(-3560.0%) | $146.03 M(-11.7%) |
| Mar 2018 | - | -$1.00 M(-101.3%) | $165.43 M(-20.5%) |
| Dec 2017 | $208.10 M(+281.1%) | $77.49 M(+121.8%) | $208.10 M(+76.4%) |
| Sept 2017 | - | $34.94 M(-35.3%) | $117.96 M(+7.1%) |
| June 2017 | - | $54.00 M(+29.6%) | $110.10 M(+103.5%) |
| Mar 2017 | - | $41.67 M(-429.4%) | $54.10 M(-0.9%) |
| Dec 2016 | $54.60 M(+28.4%) | -$12.65 M(-146.7%) | $54.60 M(-20.2%) |
| Sept 2016 | - | $27.08 M(-1456.5%) | $68.38 M(-53.2%) |
| June 2016 | - | -$2.00 M(-104.7%) | $146.06 M(-3.0%) |
| Mar 2016 | - | $42.17 M(+3638.6%) | $150.56 M(+254.1%) |
| Dec 2015 | $42.52 M | $1.13 M(-98.9%) | $42.52 M(-54.4%) |
| Sept 2015 | - | $104.76 M(+4085.3%) | $93.21 M(+38.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | - | $2.50 M(-103.8%) | $67.37 M(-11.0%) |
| Mar 2015 | - | -$65.87 M(-227.1%) | $75.69 M(-32.6%) |
| Dec 2014 | $112.32 M(+15.8%) | $51.82 M(-34.3%) | $112.32 M(+62.5%) |
| Sept 2014 | - | $78.92 M(+629.5%) | $69.14 M(+37.3%) |
| June 2014 | - | $10.82 M(-137.0%) | $50.34 M(-30.4%) |
| Mar 2014 | - | -$29.25 M(-438.4%) | $72.35 M(-25.4%) |
| Dec 2013 | $96.97 M(+144.6%) | $8.64 M(-85.6%) | $96.97 M(+96.7%) |
| Sept 2013 | - | $60.13 M(+83.2%) | $49.31 M(+38.2%) |
| June 2013 | - | $32.83 M(-809.6%) | $35.67 M(+68.4%) |
| Mar 2013 | - | -$4.63 M(-88.1%) | $21.18 M(-46.6%) |
| Dec 2012 | $39.64 M(+225.3%) | -$39.02 M(-183.9%) | $39.64 M(-65.7%) |
| Sept 2012 | - | $46.48 M(+153.5%) | $115.59 M(+56.7%) |
| June 2012 | - | $18.34 M(+32.5%) | $73.77 M(+51.3%) |
| Mar 2012 | - | $13.84 M(-62.5%) | $48.75 M(+300.1%) |
| Dec 2011 | $12.19 M(-87.6%) | $36.93 M(+692.2%) | $12.19 M(-683.0%) |
| Sept 2011 | - | $4.66 M(-169.7%) | -$2.09 M(-104.4%) |
| June 2011 | - | -$6.68 M(-70.6%) | $47.42 M(-18.1%) |
| Mar 2011 | - | -$22.72 M(-200.3%) | $57.90 M(-40.9%) |
| Dec 2010 | $98.02 M(+221.3%) | $22.66 M(-58.2%) | $98.02 M(+88.2%) |
| Sept 2010 | - | $54.17 M(+1328.6%) | $52.08 M(+66.7%) |
| June 2010 | - | $3.79 M(-78.2%) | $31.24 M(-57.4%) |
| Mar 2010 | - | $17.40 M(-174.7%) | $73.36 M(+140.4%) |
| Dec 2009 | $30.51 M(+317.0%) | -$23.29 M(-169.9%) | $30.51 M(-27.1%) |
| Sept 2009 | - | $33.34 M(-27.4%) | $41.86 M(+47.0%) |
| June 2009 | - | $45.91 M(-280.4%) | $28.47 M(-317.3%) |
| Mar 2009 | - | -$25.45 M(+113.1%) | -$13.10 M(-279.0%) |
| Dec 2008 | $7.32 M(-86.8%) | -$11.94 M(-159.9%) | $7.32 M(-92.6%) |
| Sept 2008 | - | $19.94 M(+359.4%) | $98.40 M(+44.0%) |
| June 2008 | - | $4.34 M(-186.3%) | $68.35 M(+91.8%) |
| Mar 2008 | - | -$5.03 M(-106.4%) | $35.63 M(-35.7%) |
| Dec 2007 | $55.45 M(-1465.4%) | $79.14 M(-883.0%) | $55.45 M(-334.0%) |
| Sept 2007 | - | -$10.11 M(-64.4%) | -$23.70 M(+74.4%) |
| June 2007 | - | -$28.37 M(-291.9%) | -$13.59 M(-191.9%) |
| Mar 2007 | - | $14.79 M | $14.79 M |
| Dec 2006 | -$4.06 M(-109.6%) | - | - |
| Dec 2005 | $42.25 M(+359.4%) | - | - |
| Dec 2004 | $9.20 M | - | - |
FAQ
- What is Emergent BioSolutions annual cash flow from operations?
- What is the all time high annual CFO for Emergent BioSolutions?
- What is Emergent BioSolutions annual CFO year-on-year change?
- What is Emergent BioSolutions quarterly cash flow from operations?
- What is the all time high quarterly CFO for Emergent BioSolutions?
- What is Emergent BioSolutions quarterly CFO year-on-year change?
- What is Emergent BioSolutions TTM cash flow from operations?
- What is the all time high TTM CFO for Emergent BioSolutions?
- What is Emergent BioSolutions TTM CFO year-on-year change?
What is Emergent BioSolutions annual cash flow from operations?
The current annual CFO of EBS is -$206.30 M
What is the all time high annual CFO for Emergent BioSolutions?
Emergent BioSolutions all-time high annual cash flow from operations is $536.90 M
What is Emergent BioSolutions annual CFO year-on-year change?
Over the past year, EBS annual cash flow from operations has changed by -$172.20 M (-504.99%)
What is Emergent BioSolutions quarterly cash flow from operations?
The current quarterly CFO of EBS is $153.70 M
What is the all time high quarterly CFO for Emergent BioSolutions?
Emergent BioSolutions all-time high quarterly cash flow from operations is $328.10 M
What is Emergent BioSolutions quarterly CFO year-on-year change?
Over the past year, EBS quarterly cash flow from operations has changed by +$93.70 M (+156.17%)
What is Emergent BioSolutions TTM cash flow from operations?
The current TTM CFO of EBS is $170.70 M
What is the all time high TTM CFO for Emergent BioSolutions?
Emergent BioSolutions all-time high TTM cash flow from operations is $536.90 M
What is Emergent BioSolutions TTM CFO year-on-year change?
Over the past year, EBS TTM cash flow from operations has changed by +$316.30 M (+217.24%)